Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea

A cross-sectional study in adolescents and young adults

Sherif M Badawy*, Alexis A Thompson, Jin-Shei Lai, Frank J Penedo, Karen Rychlik, Robert I Liem

*Corresponding author for this work

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea is safe and efficacious in SCD; however, adherence is suboptimal, and patients' perceptions are poorly understood amongst adolescents and young adults (AYA). Study objectives were to: (1) examine patients' perceptions of SCD and hydroxyurea; and (2) explore the relationship of their perceptions to clinical characteristics, HRQOL domains and hydroxyurea adherence. Methods: Thirty-four SCD patients on hydroxyurea (≥6 months) participated in a single-institution study. Study measures included Brief-Illness Perceptions Questionnaire,

Original languageEnglish (US)
Article number136
JournalHealth and Quality of Life Outcomes
Volume15
Issue number1
DOIs
StatePublished - Jul 5 2017

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Young Adult
Cross-Sectional Studies
Quality of Life

Keywords

  • Adherence
  • Beliefs
  • Health-related quality of life
  • Hydroxyurea
  • Patient reported outcomes
  • Perceptions
  • Sickle cell disease

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

@article{f139b7aabac2455ca2a1a3750227c4de,
title = "Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: A cross-sectional study in adolescents and young adults",
abstract = "Background: Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea is safe and efficacious in SCD; however, adherence is suboptimal, and patients' perceptions are poorly understood amongst adolescents and young adults (AYA). Study objectives were to: (1) examine patients' perceptions of SCD and hydroxyurea; and (2) explore the relationship of their perceptions to clinical characteristics, HRQOL domains and hydroxyurea adherence. Methods: Thirty-four SCD patients on hydroxyurea (≥6 months) participated in a single-institution study. Study measures included Brief-Illness Perceptions Questionnaire,",
keywords = "Adherence, Beliefs, Health-related quality of life, Hydroxyurea, Patient reported outcomes, Perceptions, Sickle cell disease",
author = "Badawy, {Sherif M} and Thompson, {Alexis A} and Jin-Shei Lai and Penedo, {Frank J} and Karen Rychlik and Liem, {Robert I}",
year = "2017",
month = "7",
day = "5",
doi = "10.1186/s12955-017-0713-x",
language = "English (US)",
volume = "15",
journal = "Health and Quality of Life Outcomes",
issn = "1477-7525",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea

T2 - A cross-sectional study in adolescents and young adults

AU - Badawy, Sherif M

AU - Thompson, Alexis A

AU - Lai, Jin-Shei

AU - Penedo, Frank J

AU - Rychlik, Karen

AU - Liem, Robert I

PY - 2017/7/5

Y1 - 2017/7/5

N2 - Background: Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea is safe and efficacious in SCD; however, adherence is suboptimal, and patients' perceptions are poorly understood amongst adolescents and young adults (AYA). Study objectives were to: (1) examine patients' perceptions of SCD and hydroxyurea; and (2) explore the relationship of their perceptions to clinical characteristics, HRQOL domains and hydroxyurea adherence. Methods: Thirty-four SCD patients on hydroxyurea (≥6 months) participated in a single-institution study. Study measures included Brief-Illness Perceptions Questionnaire,

AB - Background: Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea is safe and efficacious in SCD; however, adherence is suboptimal, and patients' perceptions are poorly understood amongst adolescents and young adults (AYA). Study objectives were to: (1) examine patients' perceptions of SCD and hydroxyurea; and (2) explore the relationship of their perceptions to clinical characteristics, HRQOL domains and hydroxyurea adherence. Methods: Thirty-four SCD patients on hydroxyurea (≥6 months) participated in a single-institution study. Study measures included Brief-Illness Perceptions Questionnaire,

KW - Adherence

KW - Beliefs

KW - Health-related quality of life

KW - Hydroxyurea

KW - Patient reported outcomes

KW - Perceptions

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=85021709604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021709604&partnerID=8YFLogxK

U2 - 10.1186/s12955-017-0713-x

DO - 10.1186/s12955-017-0713-x

M3 - Article

VL - 15

JO - Health and Quality of Life Outcomes

JF - Health and Quality of Life Outcomes

SN - 1477-7525

IS - 1

M1 - 136

ER -